EU legal and regulatory update May 2024.

This document provides a legal and regulatory update for May 2024 in the European Union (EU) regarding pharmaceutical patents and market authorizations. It highlights specific cases, such as the invalidity of Novartis' patent for fingolimod, the injunction against generic versions of sitagliptin and metformin, and the rejection of a SPC application for avelumab. The document also mentions the dismissal of requests to cancel market authorizations for the Spikevas and Cominarty COVID-19 vaccines. It discusses two separate cases related to the commercialization of medical products, one involving Mylan Ireland and the other involving Doctipharma SAS. The document further examines a complicated judgment regarding the procedure used by the European Medicines Agency (EMA) to designate its experts, as well as a judgment under appeal regarding the interpretation of a policy on competing interests in the pharmaceutical industry. [Extracted from the article]